- Home
- OBIO vs AVIR Comparison
OBIO vs AVIR Comparison
Compare OBIO & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- AVIR
- Stock Information
- Founded
- OBIO 2017
- AVIR 2012
- Country
- OBIO United States
- AVIR United States
- Employees
- OBIO N/A
- AVIR N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- OBIO Health Care
- AVIR Health Care
- Exchange
- OBIO Nasdaq
- AVIR Nasdaq
- Market Cap
- OBIO 205.0M
- AVIR 290.4M
- IPO Year
- OBIO N/A
- AVIR 2020
- Fundamental
- Price
- OBIO $5.83
- AVIR $3.56
- Analyst Decision
- OBIO Strong Buy
- AVIR Hold
- Analyst Count
- OBIO 4
- AVIR 1
- Target Price
- OBIO $15.75
- AVIR $6.88
- AVG Volume (30 Days)
- OBIO 44.2K
- AVIR 152.3K
- Earning Date
- OBIO 11-11-2024
- AVIR 11-06-2024
- Dividend Yield
- OBIO N/A
- AVIR N/A
- EPS Growth
- OBIO N/A
- AVIR N/A
- EPS
- OBIO N/A
- AVIR N/A
- Revenue
- OBIO $2,079,000.00
- AVIR N/A
- Revenue This Year
- OBIO $7.68
- AVIR N/A
- Revenue Next Year
- OBIO $110.40
- AVIR N/A
- P/E Ratio
- OBIO N/A
- AVIR N/A
- Revenue Growth
- OBIO N/A
- AVIR N/A
- 52 Week Low
- OBIO $4.22
- AVIR $2.77
- 52 Week High
- OBIO $11.69
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- OBIO 60.54
- AVIR 49.38
- Support Level
- OBIO $5.20
- AVIR $3.31
- Resistance Level
- OBIO $5.99
- AVIR $3.86
- Average True Range (ATR)
- OBIO 0.38
- AVIR 0.12
- MACD
- OBIO 0.12
- AVIR 0.03
- Stochastic Oscillator
- OBIO 87.20
- AVIR 46.90
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).